Risk of Chemotherapy-Induced Peripheral Neuropathy in Large Population-Based Cohorts of Elderly Patients With Breast, Ovarian, and Lung Cancer
Risk of Chemotherapy-Induced Peripheral Neuropathy in Large Population-Based Cohorts of Elderly Patients With Breast, Ovarian, and Lung Cancer
复制标题
DOI：
10.1097/mjt.0b013e3181a3e50b
复制
发表时间：
2010-03-01
影响因子：
4.2
通讯作者：
Du, Xianglin L.
中科院分区：
文献类型：
--
作者：
Nurgalieva, Zhannat;Xia, Rui;Du, Xianglin L.
关于化疗诱导的周围神经病变（PN）在社区居住的癌症患者中的信息很少。我们研究了65,316例乳腺癌患者，9242例卵巢癌患者和86,278例非小细胞肺癌患者，从1991年到2002年，从监测、流行病学和最终结果的16个领域确定。在接受铂紫杉烷联合化疗的乳腺癌、卵巢癌和肺癌患者中，PN的发生率密度分别为15.3、21.5和18.3 / 1000人年。接受紫杉烷治疗的乳腺癌、卵巢癌和肺癌患者发生PN的可能性是未接受化疗的患者的两倍多（乳腺癌患者调整后的风险比= 2.22,95%可信区间= 1.85-2.66），而接受铂-紫杉烷联合化疗的患者发生PN的可能性是未接受化疗的女性的3倍多（调整后的风险比= 3.33,95%可信区间= 2.05-5.05）。在接受紫杉烷或铂-紫杉烷联合治疗的卵巢癌或肺癌患者中，PN的风险随着化疗周期的增加而增加。在调整了先前存在的PN或糖尿病史后，这些发现仍然相似。密切监测单独接受紫杉烷或与铂类化合物联合使用的患者的PN可能是有必要的。
There is little information on chemotherapy-induced peripheral neuropathy (PN) for community-dwelling patients with cancer. We studied 65,316 patients with breast cancer, 9242 with ovarian cancer, and 86,278 with non-small cell lung cancer from 1991 through 2002 identified from the 16 areas of Surveillance, Epidemiology and End Results. The incidence density of PN was 15.3, 21.5, and 18.3 per 1000 person-years for patients with breast, ovarian, and lung cancer who received platinum taxane combination chemotherapy, respectively. Patients with breast, ovarian, and lung cancer receiving taxanes were more than twice as likely to develop PN compared with those not receiving chemotherapy (adjusted hazard ratio = 2.22, 95% confidence interval = 1.85-2.66 in patients with breast cancer), whereas patients who received platinum-taxane combination chemotherapy were more than 3 times as likely to develop PN compared with women who did not receive chemotherapy (adjusted hazard ratio = 3.33, 95% confidence interval = 2.05-5.05). In patients with ovarian or lung cancer receiving taxanes or platinum-taxane combination therapy, the risk of PN was increased with increasing number of chemotherapy cycles. These findings remained similar after adjusting for the history of preexisting PN or diabetes. Close monitoring for PN in patients receiving taxanes alone or in combination with platinum compounds may be warranted.